CLLS - Earnings announcements

Pivotal Phase 2 with lasme-cel in r/r B-ALL (BALLI-01 trial)  Pivotal Phase 2 first interim analysis expected in Q4 2026BLA submission anticipated in 2028 Phase 1 with eti-cel in r/r NHL (NATHALI-01 trial) Full Phase 1 dataset expected in Q4 2026 Innovation Preclinical data on TALE-based epigenetic editing, a non-DNA cutting approach, to be presented at ASGCT Servier (through Allogene): Interim pivotal data reported from the ALPHA3 trial of cema-cel (n=24) 58.3% of patients in the cema-cel arm achieved MRD negativity versus 16.7% in the observation armFavorable safety profile: no cases of CRS, ICANS, GvHD, or Treatment-Related Serious Adverse EventsStudy accrual expected to be comple

NEW YORK, May 04, 2026 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the first quarter 2026 ending March 31, 2026 on Monday, May 11, 2026 after the close of the US market. The press release will be available in the Investors section of Cellectis' website: https://www.cellectis.com/en/investors/press-releases/ Cellectis will not host a conference call to discuss these results. Our investor relations team remains available for questions at investors@cellectis.com About Cellectis Cellectis

NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- Cellectis (the "Company") ((Euronext Growth: ALCLS, NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the fourth quarter and full year 2025 ending December 31, 2025 on Thursday, March 19, 2026 after the close of the US market. The publication will be followed by an investor conference call and webcast on Friday, March 20, 2026, at 8:00 AM ET / 1:00 PM CET. The call will include the Company's fourth quarter and full year 2025 results and an update on business activities. Details for the call are

NEW YORK, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the third quarter 2025 ending September 30, 2025 on Friday, November 7, 2025 after the close of the US market. The press release will be available in the Investors section of Cellectis' website: https://www.cellectis.com/en/investors/press-releases/ Cellectis will not host a conference call to discuss these results. Our investors relations team remains available for questions at investors@cellectis.com About CellectisC

Cellectis to host an Investor R&D Day in New York City on October 16, 2025: Phase 1 dataset and late-stage development strategy for lasme-cel (UCART22) in r/r B-ALL to be presented End-of-Phase 1 meetings with FDA & EMA for lasme-cel (UCART22) in r/r B-ALL completed in July 2025; on track to launch pivotal Phase 2 in H2 2025  Servier arbitration: arbitral decision expected to be rendered on or before December 15, 2025 eti-cel (UCART20x22): Phase 1 study in r/r NHL ongoing with readout expected in late 2025  AstraZeneca partnership: R&D activities are continuing to advance for the three programs initiated Appointment of Mr. André Muller as Director to Cellectis' Board of Directors Cash, cash

NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the second quarter 2025 ending June 30, 2025 on Monday August 4, 2025 after the close of the US market. The publication will be followed by an investor conference call and webcast on Tuesday August 5, 2025 at 8:00 AM ET / 2:00 PM CET. The call will include the Company's second quarter results and an update on business activities. Details for the call are as follows: Dial in information: Domestic: +1-800-343-5172 Inte

Lasme-cel (UCART22) Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025Eti-cel (UCART20x22) Phase 1 study in relapsed or refractory B-cell non-Hodgkin lymphoma (r/r NHL) ongoing with readout expected in late 2025AstraZeneca partnership: R&D activities ongoing on three programs – one allogeneic CAR T for hematological malignancies, one allogeneic CAR T for solid tumors, and one in vivo gene therapy for a genetic disorderCellectis will present novel non-viral gene editing and base editing research at the 2025 ASGCT annual meetingCash position of $246 million as of March 31, 20251 provides runway into H2 2027 NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Ce

NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the first quarter 2025 ending March 31, 2025 on Monday, May 12, 2025 after the close of the US market. The press release will be available in the Investors section of Cellectis' website: https://www.cellectis.com/en/investors/press-releases/ Cellectis will not host a conference call to discuss these results. Our investors relations team remains available for questions at investors@cellectis.com      About Cellectis  Ce

○ UCART22 Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025; Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) granted by FDA and ODD granted by the European Commission to UCART22 for the treatment of ALL. ○ UCART20x22 Phase 1 study in relapsed or refractory B-cell non-Hodgkin lymphoma (r/r NHL) ongoing with readout expected in late 2025. ○ AstraZeneca partnership: R&D activities ongoing on three programs – one allogeneic CAR T for hematological malignancies, one allogeneic CAR T for solid tumors, and one in vivo gene therapy for a genetic disorder. ○ Cash position of $264 million as of December 31, 20241 provides runway in

NEW YORK, March 07, 2025 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the fourth quarter and full year 2024 ending December 31, 2024 on Thursday, March 13, 2025 after the close of the US market. The publication will be followed by an investor conference call and webcast on Friday, March 14, 2025, at 8:00 AM ET / 1:00 PM CET. The call will include the Company's fourth quarter and full year 2024 results and an update on business activities. Details for the call are as follows: Di

NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) --  Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the third quarter 2024 ending September 30, 2024 on Monday, November 4, 2024 after the close of the US market. The publication will be followed by an investor conference call and webcast on Tuesday, November 5, 2024 at 8:00 AM ET / 2:00 PM CET. The call will include the Company's third quarter results and an update on business activities. Details for the call are as follows: Dial in information: Domestic: +1-800-225-9

ODD and RPDD granted by the FDA and ODD granted by the European Commission to UCART22 for the treatment of ALLODD granted by the FDA to CLLS52 (alemtuzumab) for ALL treatmentCash position of $273 million as of June 30, 20241; cash runway projection into 2026 NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today provided business updates and reported financial results for the six-month period ending June 30, 2024. "Over the past months, we have achieved a significant milestone with the granting of ODD designations by

•  Cellectis announced completion of the additional equity investment of $140M by AstraZeneca •  Cash position of $143 million as of March 31, 20241; cash runway projection into 20262 •  Conference call and webcast scheduled for tomorrow, May 29, 2024 at 8:00AM ET / 2:00PM CET NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today provided business updates and reported financial results for the three-month period ending March 31, 2024. "We are thrilled to have announced the closing of the additional equity investment of $14

NEW YORK, May 27, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the first quarter 2024 ending March 31, 2024 on Tuesday, May 28, 2024 after the close of the US market. The publication will be followed by an investor conference call and webcast on Wednesday, May 29, 2024 at 8:00 AM ET / 2:00 PM CET. The call will include the Company's first quarter results and an update on business activities. Details for the call are as follows: Dial in information: Domestic: 1-877-451-6152 Interna

•   Preliminary results of NATHALI-01 and updated results of BALLI-01 Phase I clinical studies presented at the American Society of Hematology (ASH) 65th Annual Meeting •   Execution of strategic collaboration and investment agreements with AstraZeneca •   Cécile Chartier, Ph.D., appointed as a director of the Cellectis' Board of Directors •   Drawdown of the second tranche of €15 million under the credit facility agreement entered into with the European Investment Bank (EIB) •   Cash position of $156 million as of December 31, 20231 NEW YORK, April 29, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene ed

•  Strategic Collaboration and Investment Agreements signed with AstraZeneca Updated results of the Phase I BALLI-01 Trial evaluating UCART22 in r/r B-cell ALL and preliminary results of the Phase I NATHALI-01 Trial evaluating UCART20x22 in r/r B-cell NHL to be presented at ASH 65th Annual meeting.Clinical trials ongoing: BALLI-01 (evaluating UCART22), NATHALI-01 (evaluating UCART20x22) and AMELI-01 (evaluating UCART123) studies for patients with r/r B-cell ALL, r/r B-cell NHL and r/r AML, respectively.Preclinical data on HSPC gene therapy and a comprehensive analysis of TALE-BE editing determinants presented at ESGCT 2023 30th annual congress.Preclinical data on Multi-armored Allogeneic MU

NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the third quarter ended September 30, 2023 on Monday, November 6, 2023 after the close of the US market. The announcement will be followed by an investor conference call and webcast on Tuesday, November 7, 2023 at 8:00 AM ET / 2:00 PM CET. The call will include the Company's third quarter results and an update on business activities. Details for the call are as follows: Dial in information: Domestic: 1-877-451-6152 In

Updated clinical & translational data on BALLI-01 trial (evaluating UCART22 in r/r B-cell ALL) presented at the EHA annual meeting Clinical trials ongoing: BALLI-01 (evaluating UCART22), NATHALI-01 (evaluating UCART20x22) and AMELI-01 (evaluating UCART123) studies for patients with r/r B-cell ALL, r/r B-cell NHL and r/r AML, respectively Preclinical data presented on HBB gene correction of sickle cell mutation & TALE Base Editors (TALE-BE) at ISCT 2023 annual event Appointment of Cécile Chartier, Ph.D., as Director to Cellectis' Board of Directors Cash position1 of $89 million as of June 30, 2023. Cash runway into Q3 2024 Full financial statements for the second quarter of 2023 will be

NEW YORK, July 27, 2023 (GLOBE NEWSWIRE) -- Cellectis S.A. (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the second quarter ended June 30, 2023 on Thursday, August 3, 2023 after the close of the US market. The announcement will be followed by an investor conference call and webcast on Friday, August 4, 2023 at 8:00 am ET / 2:00 pm CET. The call will include the Company's second quarter results and an update on business activities. Details for the call are as follows: Dial in information: Domestic: 1-877-451-6152 Int

First r/r ALL patient dosed in Europe with Cellectis' UCART22 product candidate manufactured in-houseCellectis implements CLLS52 for the first time in the clinic with Sanofi's alemtuzumabCellectis stops enrollment and treatment of patients in the MELANI-01 clinical trial evaluating UCARTCS1 product candidate in r/r MMEncouraging preclinical data on TALEN®-edited MUC1 CAR T-cells presented at the AACR 2023 annual meetingTwo abstracts accepted for oral and poster presentations at the upcoming ASGCT annual meetingCash position1 of 88$ million as of March 31, 2023Conference call scheduled for 8AM ET/2PM CET on May 5, 2023 NEW YORK, May 04, 2023 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (N

NEW YORK, April 27, 2023 (GLOBE NEWSWIRE) -- Cellectis (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the first quarter ended March 31, 2023, on Thursday, May 4, 2023 after the close of the US market. The announcement will be followed by an investor conference call and webcast on Friday, May 5, 2023 at 8:00 am ET / 2:00 pm CET. The call will include the Company's first quarter results and an update on business activities. Details for the call are as follows: Dial-in Information:Domestic:1-877-451-6152International:1-201-389-0879Confere

Entered into a €40 million credit facility with the European Investment Bank and closed an approximatively $25 million follow-on equity offering to support Cellectis' research, development and innovation activities Positive preliminary clinical data from Phase 1 BALLI-01 study (evaluating UCART22) for patients with r/r B-cell ALL presented in a Live Webcast; First patient dosed with UCART22 product candidate fully manufactured in-house Encouraging preliminary results from Phase 1 AMELI-01 study (evaluating UCART123) for patients with AML presented at an oral session at ASH 2022; AMELI-01 currently enrolling in a two-dose regimen arm at DL2 Partner Allogene Therapeutics initiated Phase 2

NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- Cellectis (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the fourth quarter and year-end 2022 ending December 31st, 2022, on Wednesday, March 8, 2023, after the close of the US market. The announcement will be followed by a conference call and live audio webcast on Thursday, March 9, 2023, at 8:00 AM ET / 2:00 PM CET. The call will include the Company's fourth quarter results, year-end results, and an update on business activities. Details for the call are as follows: Dial-in information:

ASH 2022 sponsored programs – UCART123 abstract selected for oral presentation & preclinical data on UCARTCS1 selected for poster presentation, in collaboration with the Amsterdam University Medical Center Preclinical data on TALEN®-edited smart CAR T-cells to be presented at SITC 2022 Partner Allogene Therapeutics announced having initiated industry's first allogeneic CAR T Phase 2 trial Iovance Biotherapeutics, Inc. announced having dosed the first patient and completed safety observation period in its IOV-GM1-201 clinical trial Mark Frattini, M.D., Ph.D., appointed Chief Medical Officer Cash position1 of $103 million as of September 30, 2022 Conference call scheduled for 8AM ET/2PM

NEW YORK, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Cellectis (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the third quarter ended September 30th, 2022, on Thursday, November 3rd, 2022, after the close of the US market. The announcement will be followed by a conference call and live audio webcast on Friday, November 4th, 2022, at 8:00 AM EDT / 2:00 PM CET. The call will include the Company's third quarter results and an update on business activities. Details for the call are as follows: Friday, November 4th at 8:00 a.m. Eastern Time:Domestic

  IND clearance received from FDA for UCART20x22 for the treatment of Non-Hodgkin LymphomaCellectis unveiled novel immune-evasive universal allogeneic CAR T-cell in Nature Communications; awarded oral presentation at ASGCT in MayMr. Axel-Sven Malkomes & Dr. Donald A Bergstrom, M.D., Ph.D. appointed as Directors of Cellectis' Board of DirectorsCash position1 of $135 million as of June 30, 2022 Conference call scheduled for 8AM ET/2PM CET on August 5, 2022 NEW YORK, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today provided busines

NEW YORK, July 28, 2022 (GLOBE NEWSWIRE) -- Cellectis (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the second quarter ended June 30th, 2022, on Thursday, August 4th, 2022, after the close of the US market. The announcement will be followed by a conference call and webcast on Friday, August 5th, 2022, at 8:00 AM EDT / 2:00 PM CET. The call will include the Company's second quarter results and an update on business activities. Details for the call are as follows: Friday, August 5th at 8:00 am Eastern Time:Domestic:1-877-451-6152Interna

◦   UCART20x22 preclinical data presented at AACR demonstrated PoC with robust in vitro and in vivo anti-tumor activity ◦   Published two articles in Nature Communications providing preclinical validation for the evaluation of UCART123 to treat AML and BPDCN ◦   Received a $20 million convertible note under collaboration agreement with its partner Cytovia Therapeutics ◦   The US FDA has allowed an IND to proceed for Iovance Biotherapeutics' first genetically modified TIL therapy, which is leveraging TALEN® gene editing technology ◦   Cash position [1] of $142 million as of March 31, 2022 ◦   Conference call scheduled for 8AM ET/2PM CET on May 13, 2022 [1] Cash position includes c

NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the first quarter ended March 31st, 2022, on Thursday, May 12th, 2022, after the close of the US market. The announcement will be followed by a conference call and live audio webcast on Friday, May 13th, 2022, at 8:00 AM EDT / 2:00 PM CET. The call will include the Company's first quarter results and an update on business activities. Details for the call are as follows:Dial In Information: Friday, May 13th, 8:00 AM EDT /

Encouraging preliminary results from BALLI-01 study (evaluating UCART22) in relapsed/refractory B-cell Acute Lymphoblastic Leukemia presented at ASH 2021 annual meeting; BALLI-01 currently enrolling at DL3 On track for planned 2022 IND submission for UCART20x22, our first allogeneic dual CAR T-cell product candidate, in B-cell non-Hodgkin's LymphomaTwo manufacturing sites are now fully operational; on-track to dose patients with investigational medicinal products manufactured in-house in 2022Cash position1 of $191 million as of December 31, 2021Conference call scheduled for 8AM ET/2PM CET on March 4, 2022 NEW YORK, March 03, 2022 (GLOBE NEWSWIRE) -- Cellectis (NASDAQ:CLLS), a clinica

NEW YORK, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Cellectis (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced that it will report its financial results for the fourth quarter and year-end 2021 ending December 31, 2021, on Thursday, March 3, 2022, after the close of the US market. The announcement will be followed by a conference call and live audio webcast on Friday, March 4, 2022, at 8:00 AM EDT / 2:00 PM CET, prior to the open of the US market. The call will include the Company's fourth quarter results, year-end results, and an update on business activities. Details for the call are as fol

•   Sponsored programs at ASH 2021 - preliminary clinical data to be presented at ASH 2021 for product candidate UCART22 and preclinical data from Cellectis gene therapy product candidate TALGlobin01 •   Partnered programs at ASH 2021 – ALPHA2 and UNIVERSAL abstracts selected for oral presentations, ALPHA abstract selected for poster presentation •   Preclinical data for RAG1 deficiency Severe Combined Immunodeficiency (SCID) and STAT3 for Hyper IgE syndrome presented at ESGCT 2021 •   Preclinical data supporting anti-tumor activity of UCARTMESO to be presented at SITC 2021 on November 12, 2021 •   Qualification of facility equipment and systems completed for •   Raleigh GMP manufacturi

NEW YORK, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ:CLLS) (the "Company"), a gene-editing platform company with clinical-stage immuno-oncology programs using allogeneic chimeric antigen receptor (CAR)-T cells and gene therapy programs for genetic diseases, announced that it will report its financial results for the third quarter and first nine-month period ending September 30, 2021, on Thursday, November 4, 2021, after the close of the US market. The announcement will be followed by a conference call at 8:00 AM EDT / 2:00 PM CET on Friday, November 5, 2021, prior to the open of the US market. The live dial-in information for the conference call is: US & Canada only: +1

• Preliminary translational data validate UCARTCS1 as a promising potential therapy for relapsed orrefractory multiple myeloma patients. • Preclinical pipeline disclosed at Innovation Days : UCART20x22 for B-cell malignancies, UCARTMESO(targeting mesothelin), and TALGlobin01 (Sickle Cell Disease) • First mRNA batches and UCART training runs successfully completed in our proprietary GMP facilities • Cash position1 of $257 million as of June 30, 2021. Cash runway into 2023 NEW YORK, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ:CLLS) (the "Company"), a gene-editing platform company with clinical-stage immuno-oncology programs using allogeneic chimeric antigen receptor (CAR) T-

NEW YORK, July 29, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ:CLLS) (the "Company"), a gene-editing platform company with clinical-stage immuno-oncology programs using allogeneic chimeric antigen receptor (CAR) T-cells and gene therapy programs for monogenic diseases, announced that it will report its financial results for the second quarter and first six-month period ending June 30, 2021, on Thursday, August 5, 2021, after the close of the US market. The announcement will be followed by a conference call at 8:00 AM EDT / 2:00 PM CET on Friday, August 6, 2021, prior to the open of the US market. The live dial-in information for the conference call is: US & Canada only: +1 (877) 407-

Enrollment ongoing in three Cellectis-sponsored Phase 1 dose-escalation clinical studies BALLI-01 in r/r B-ALL patients, AMELI-01 in r/r AML patients and MELANI-01 in r/r MM patients in 15 US clinical centers Five partnered allogeneic CAR-T product candidates in clinical development through our collaborations with Allogene and Servier: UCART19/ALLO-501 and ALLO-501A in r/r NHL, ALLO-715 and ALLO-605 in r/r MM and ALLO-316 in advanced or metastatic clear cell renal cell carcinoma New collaboration with Cytovia Therapeutics, Inc. to develop TALEN® gene-edited iPSC-derived NK and CAR-NK cell programs, including solid tumor targets Successful manufacturing of first starting materials for UCAR